Effects of E-cigarettes on Combustible Cigarette Smoking Among Adults With Opioid Use Disorder on Buprenorphine: Single Arm ERASER Pilot Trial
Nicotine and Tobacco Research · 2025
DOI: 10.1093/ntr/ntae260 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nicotine and Tobacco Research, 2025. Verfasst von Irene Pericot-Valverde und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, Clemson University, Clemson, SC, USA. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders, Electronic Nicotine Delivery Systems, Cigarette Smoking. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Clemson Faculty SUCCEEDS, NIDA NIH HHS, Clemson University.
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Introduction
People with opioid use disorder (OUD) on buprenorphine smoke at high rates and have low cessation rates, even with evidence-based medications. Electronic cigarettes (EC) are a promising harm reduction strategy for combusted cigarette (CC) smokers unable to quit. Unfortunately, people with OUD are underrepresented in EC research. Aims and Methods A pilot study assessed the feasibility, acceptability, and preliminary effectiveness of EC as a harm reduction tool among CC smokers with OUD on buprenorphine (N = 30). Participants were provided with an EC and freebase nicotine liquid (6 mg/mL) with a choice of flavor and a brief training session. Research visits were scheduled in person at baseline, week 4, and week 8 (follow-up). Daily diary assessments were completed during the 4-week EC period.
Results
Most visits (>74%) and 61.4% of daily diary assessments were completed. During the 4-week study period, 90% of participants used the EC at least one day, 66.7% used the EC for at least 16 days, and 43.3% used the EC every day. Significant reductions were observed between baseline and both weeks 4 and 8 in cigarettes smoked per day (CPDbaseline = 16.2[8.3], CPDweek4 = 9.6[9.3], CPDweek8 = 8.4[8.3]) carbon monoxide (CO) levels (CObaseline = 21.5[15.0], COweek4 = 16.9[9.6], COweek8 = 15.7[10.0]), and nicotine dependence measured using the Fagerström Test for Nicotine Dependence (FTNDbaseline = 5.4[2.5], FTNDweek4 = 4.2[2.6], FTNDweek8 = 4.4[2.6]), with all p-values < .05.
Conclusions
Implementing an EC protocol in outpatient maintenance treatment programs is feasible and acceptable. Preliminary results suggest that ECs may facilitate reductions in cigarettes per day, CO levels, and nicotine dependence. Future research should explore the effect of prolonged EC use on harm reduction and cessation milestones.
Implications
EC are a potentially promising harm reduction strategy for adult CC smokers with OUD on buprenorphine who are unable to quit using evidence-based medications. However, previous studies have largely overlooked people with OUD on buprenorphine with recent drug use. This study addresses this gap through a pilot trial investigating the feasibility, acceptability, and preliminary effects of EC on CC behavior. The brief and standardized nature of the protocol and its implementation in outpatient settings highlights its potential for widespread implementation in facilities providing care to people with OUD on buprenorphine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychology, Clemson University, Clemson, SC, USA.
- Department of Public Health Sciences, Clemson University, Clemson, SC, USA.
- Department of Medicine and Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY, USA.
- USC School of Medicine Greenville, University of South Carolina, Greenville, SC, USA.
- Prisma Health Addiction Medicine Center, Prisma Health, Greenville, SC, USA.
- Division of Cardiovascular Medicine, University of Texas Medical Branch, Galveston, TX, USA.
ORCID-Profile: Irene Pericot-Valverde, Moonseong Heo, James F Thrasher, Abigail W Batchelder, Kaileigh A Byrne, Alain H Litwin
Förderung
- Clemson Faculty SUCCEEDS
- NIDA NIH HHS
- Clemson University
- Prisma Health Addiction Medicine Center
- NIH
Zitieren
APA
Pericot-Valverde, I., Heo, M., Nahvi, S., Barron, J., Voss, S., Ortiz, E. G., Gaalema, D., Thrasher, J. F., Batchelder, A. W., Byrne, K. A., Kunkel, D., & Litwin, A. H. (2025). Effects of E-cigarettes on Combustible Cigarette Smoking Among Adults With Opioid Use Disorder on Buprenorphine: Single Arm ERASER Pilot Trial. Nicotine and Tobacco Research. https://doi.org/10.1093/ntr/ntae260
Vancouver
Pericot-Valverde I, Heo M, Nahvi S, Barron J, Voss S, Ortiz EG, et al. Effects of E-cigarettes on Combustible Cigarette Smoking Among Adults With Opioid Use Disorder on Buprenorphine: Single Arm ERASER Pilot Trial. Nicotine and Tobacco Research. 2025. doi:10.1093/ntr/ntae260
BibTeX
@article{PericotValverde2025,
author = {Pericot-Valverde, Irene and Heo, Moonseong and Nahvi, Shadi and Barron, Justin and Voss, Sarah and Ortiz, Erik G and Gaalema, Diann and Thrasher, James F and Batchelder, Abigail W and Byrne, Kaileigh A and Kunkel, Deborah and Litwin, Alain H},
title = {Effects of E-cigarettes on Combustible Cigarette Smoking Among Adults With Opioid Use Disorder on Buprenorphine: Single Arm ERASER Pilot Trial},
journal = {Nicotine and Tobacco Research},
year = {2025},
doi = {10.1093/ntr/ntae260}
}
EUVIMED